The Green Organic Dutchman Holdings Ltd. (the “Company” or “TGOD”) (TSX:TGOD) (US:TGODF) is pleased to announce that it has secured a cannabis supply agreement with the BC Liquor Distribution Branch (“BCLDB”).

The BCLDB, under the brand BC Cannabis Stores, is British Columbia’s public retailer of non-medical cannabis.

The idea of high-return investments is intriguing to all investors. The cannabis sector is a perfect example. Fortunes have been made in the industry, but now that legalization has come and gone, are there any opportunities left in the space?

Horizons Marijuana Life Sciences Index ETF (TSX:HMMJ) is the ideal way for investors to gain exposure to the cannabis industry without taking on specific business and execution risk. The fund consists of all the top companies in the marijuana space and is just over two years old.

The 2019 rally in marijuana stocks has investors scouring the cannabis sector to see which marijuana companies might be the best picks to pocket some pot stock gains through the end of the year. Let’s take a look at Aurora Cannabis (TSX:ACB)(NYSE:ACB) to see if it deserves to be on your buy list right now.

Medical cannabis patients still face too many practical barriers to access in countries where the drug is legal, including Canada, an international panel of advocates and experts at the Business of Cannabis Medical Cannabis conference in Toronto said Wednesday.

Long considered an international leader on medical cannabis, Canada has had a legal framework since 2001.

But with recreational legalization, we started to see two systems, said Gerald Major, president of Canadians for Fair Access to Medical Marijuana, a medical cannabis patient and an arthritis survivor.

Since the beginning of 2019, few industries have generated buzz quite like the marijuana industry. The Horizons Marijuana Life Sciences ETF, the first tradable cannabis exchange-traded fund, is up 49% for the year through Monday, May 6. That almost triples the 17% return of the broad-based S&P 500 since the year began.

About a year ago, the head of a cannabis company approached genetic technology expert John Lem with a problem; why did he have an adverse reaction from pot when everyone else who had smoked the same joint seemed fine?

So Lem set out to find whether there was a genetic explanation for the different ways people react to THC, and that's how his Toronto-based company Lobo Genetics was born.

"Looking into the science, we came to the conclusion that there is actually a genetic basis for someone's reaction to THC," said Lem.

Through a simple cheek swab, Lobo Genetics examines three genes to see how your body interacts with THC.

Hi there, Fools. I’m back to call your attention to three attractive mid-cap stocks — or, as I like to call them, my top “sweet-spot” stocks. As a quick refresher, I do this because mid-cap companies — those with a market cap of between $2 billion and $10 billion — have two key features:

Support for recreational cannabis among Canadians has dropped since the drug was legalized last year amid a shaky roll-out of legal pot and a still-robust black market, according to a survey published Thursday. 

In a survey conducted by Dalhousie University and the University of Guelph, half of Canadians support the legalization of recreational cannabis, down from about 69 per cent back in 2017. Meanwhile, uncertain sentiment surrounding legalization has grown to 20 per cent of the country, up from about 7 per cent two years ago, the survey found. 

The marijuana industry is evolving at a breakneck pace. What had once been an industry that was forced into seclusion is now an industry that has a product that's considered mainstream throughout much of North America and Europe.

Not to mention, more and more people favor the idea of legalizing cannabis, at least in the United States.